# CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

> **NCT03568422** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 37 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** CFI-402257
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03568422
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-02-05
- **Primary completion:** 2022-11-21
- **Final completion:** 2026-12-31
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568422, "CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT03568422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*